can106
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 8, 2021 (NCT05095168)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
C5AR1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05539248 | Phase 1/Phase 2 (Phase 2) | Mar 25, 2022 | Chinese Academy of Medical Sciences, Government of China |
| NCT05095168 | Phase 1 | Feb 8, 2021 | CANbridge Life Sciences Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CANbridge Life Sciences Ltd. | For profit | 1 | 1 | 1 | 2021 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Government of China | Government | 1 | 1 | 1 | 2022 |
3 organizations
Page 1 / 1